enGene Therapeutics Inc. (ENGN)
Nasdaq: ENGN · Biological Products, (No Diagnostic Substances) · Saint-Laurent, QC · filing with the SEC since 2023
The company now
enGene Therapeutics Inc. is classed by the SEC under Biological Products, (No Diagnostic Substances) (industry code 2836), based in Saint-Laurent, QC. In its latest annual figures on file, for the fiscal year ended 2025-10-31, it reported a loss of $117 million (its filed statements).
From its filings and filed figures; the desk's account of it is not written yet.
The desk's written account, its read of the annual report, the record in brief and the split of the revenue are not on file for this company yet.